Clinical

Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Clinical

Telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients

YANTAI, China, Nov. 15, 2023. RemeGen Co., Ltd. (“RemeGen” or “the Company”), a commercial-stage biotechnology company, is invited to present telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in a Late-Breaking Abstract Oral Presentation Session by the American College of Rheumatology(RA). According to the abstract, this Phase III, randomized, double-blind study evaluated the […]
Written by
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Clinical

Wegovy (semaglutide) Injection 2.4 mg Cardiovascular Outcomes Data Presented at the American Heart Association Scientific Sessions and Simultaneously Published in the New England Journal of Medicine

PLAINSBORO, N.J., November 11, 2023 – Novo Nordisk today announced the full results of SELECT, its landmark phase 3 cardiovascular outcomes trial investigating the effects of once-weekly Wegovy® (semaglutide) injection 2.4 mg in adults with established cardiovascular disease (CVD) and overweight or obesity but without diabetes, at the American Heart Association (AHA) annual Scientific Sessions […]
Written by
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Clinical

Post Hoc Analysis Showed CIMZIA Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF)

ATLANTA, Nov. 11, 2023. CB, a global biopharmaceutical company, will present a post hoc analysis of the EXXELERATE trial examining the efficacy of CIMZIA (certolizumab pegol) and adalimumab in patients with rheumatoid arthritis (RA) with high rheumatoid factor (RF) levels. The data are being presented at the American College of Rheumatology (ACR) Convergence 2023 in […]
Written by
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Clinical

Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers

Preliminary data from Arm A1 of the Phase 2 EDGE-Gastric study showed promising ORR and six-month PFS results, irrespective of PD-L1 expression Domvanalimab is the only Fc-silent anti-TIGIT antibody in Phase 3 for upper GI adenocarcinomas and has the potential to be first to market for these cancers FOSTER CITY, Calif., & […]
Written by
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Clinical

Phase 2 Nipocalimab Data Establish Proof of Mechanism in Adults Living with Moderate to Severe Rheumatoid Arthritis, Supporting its Progression into a Combination Study

SPRING HOUSE, Pa., Nov. 7, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from the Phase 2a IRIS-RA clinical study for the treatment of adults living with moderate to severe active rheumatoid arthritis (RA) who have tested positive for anti-citrullinated protein antibodies (ACPAs)a and/or rheumatoid factor (RF), and who […]
Written by
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Clinical

Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis

OSAKA Japan and CAMBRIDGE, Massachusetts, November 7, 2023 – Takeda (TSE:4502/NYSE:TAK) today announced that the company will present positive results from its randomized, double-blind, placebo-controlled, Phase 2b trial evaluating TAK-279, an investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor with next generation selectivity, in patients with active psoriatic arthritis. These data (Abstract #L12) will be […]
Written by
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Clinical

FDA Approves Zepbound for Chronic Weight Management, a New Treatment of Obesity or Overweight with Weight-Related Medical Problems

INDIANAPOLIS, Nov. 8, 2023. The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company’s (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Zepbound is indicated for adults with obesity (with a BMI of 30 […]
Written by
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Clinical

Amgen Presents New Data From Phase 2 Trial of Dazodalibep in Sjögren’s Syndrome

THOUSAND OAKS, Calif., Nov. 7, 2023. Amgen (NASDAQ:AMGN) today announced new data from its Phase 2 study evaluating dazodalibep, an investigational medicine, for the treatment of Sjögren’s. These results will be featured in presentations at the American College of Rheumatology (ACR) Convergence 2023, Nov. 10-15, in San Diego. Findings from the study demonstrate that dazodalibep […]
Written by
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Clinical

US Study Reveals CP-GEP’s Profound Impact on Stratifying Melanoma Patients for Long-Term Survival

ROTTERDAM, Netherlands and SAN DIEGO, Nov. 6, 2023 . SkylineDx, an innovative molecular diagnostics company, is pleased to announce the forthcoming presentation of an impactful poster by Dr M.E. Egger at the upcoming Society for Melanoma Research Congress in Philadelphia. Dr. M.E. Egger’s presentation promises to usher in a new paradigm in disease staging and […]
Written by
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Clinical

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic Zoliflodacin to Treat Uncomplicated Gonorrhea

This is the first study to address a World Health Organization priority pathogen that has been sponsored and led by a non-profit organization. These positive preliminary findings offer hope for patients with this condition, particularly in the face of rising antibiotic resistance to current regimens. It also paves the way for a new […]
Written by

Good Reads

New tentative approval for Alembic drug dabigatran etexilate mesylate

New patent for Vanda Pharms drug HETLIOZ

Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Annual Drug Patent Expirations for HETLIOZ Hetlioz is a drug marketed by Vanda Pharms Inc and is included in two NDAs. It is available from one supplier. There are thirty patents protecting this drug and two Paragraph IV challenges. Drug patent litigation for HETLIOZ. This drug has one […]
Written by

A proteome-wide yeast degron collection for the dynamic study of protein function

Genome-wide collections of yeast strains, known as libraries, revolutionized the way systematic studies are carried out. Specifically, libraries that involve a cellular perturbation, such as the deletion collection, have facilitated key biological discoveries. However, short-term rewiring and long-term accumulation of suppressor mutations often obscure the functional consequences of such perturbations. We present the AID library […]
Written by

Worlwide

New tentative approval for Alembic drug dabigatran etexilate mesylate

New patent for Vanda Pharms drug HETLIOZ

Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Annual Drug Patent Expirations for HETLIOZ Hetlioz is a drug marketed by Vanda Pharms Inc and is included in two NDAs. It is available from one supplier. There are thirty patents protecting this drug and two Paragraph IV challenges. Drug patent litigation for HETLIOZ. This drug has one […]
Written by

A proteome-wide yeast degron collection for the dynamic study of protein function

Genome-wide collections of yeast strains, known as libraries, revolutionized the way systematic studies are carried out. Specifically, libraries that involve a cellular perturbation, such as the deletion collection, have facilitated key biological discoveries. However, short-term rewiring and long-term accumulation of suppressor mutations often obscure the functional consequences of such perturbations. We present the AID library […]
Written by

Columbia Climate School Hosts Ninth Annual Sustainability Careers Reception – State of the Planet

Practitioners who attended the 2024 Sustainability Careers Reception. (*See below for names and affiliations) Last month, the Columbia Climate School hosted its ninth annual Sustainability Careers Reception at the Columbia Club in Midtown Manhattan. Thirty-three sustainability professionals and 88 Columbia students from varying backgrounds and degree pursuits gathered to discuss the ever-pressing challenges and real-world […]
Written by

Trending

Login

Welcome to Life Science News!
"Explore the Latest Discoveries and Breakthroughs in Life Science with Life Science News!"
Read Smart, Save Time
Pick all the topics you are interested in to fill your homepage with stories you'll love.
Join our community
Registration is closed.